References
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
[2] WANG M, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine. 2021;27(8):1345-56.
[3] LANCASTER H L, HEUVELMANS M A, OUDKERK M. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research. Journal of internal medicine. 2022;292(1):68-80.
[4] CAMIDGE D R, DOEBELE R C, KERR K M. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature reviews Clinical oncology. 2019;16(6):341-55.
[5] LI Z, FEIYUE Z, GAOFENG L. Traditional Chinese medicine and lung cancer--From theory to practice. Biomedicine & pharma-cotherapy = Biomedecine & pharmacotherapie. 2021;137:111381.
[6] WANG X, HOU L, CUI M, et al. The traditional Chinese medicine and non-small cell lung cancer: from a gut microbiome perspective. Frontiers in cellular and infection microbiology. 2023;13:1151557.
[7] JIANG R, HU C, LI Q, et al. Sodium new houttuyfonate suppresses metastasis in NSCLC cells through the Linc00668/miR-147a/slug axis. Journal of experimental & clinical cancer research: CR. 2019;38(1):155.
[8] XU L, MENG X, XU N, et al. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. Cell death & disease. 2018;9(3):262.
[9] YAO C, SU L, ZHANG F, et al. Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis. Cancer letters. 2020;493:167-77.
[10] COMMISSION C P. Pharmacopoeia of People’s Republic of China. Beijing: China Medical Science Press. 2020:271-2.
[11] WANG K, CHEN Q, SHAO Y, et al. Anticancer activities of TCM and their active components against tumor metastasis. Bio-medicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021;133:111044.
[12] LAI L, SHEN Q, WANG Y, et al. Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling. Toxicology and applied pharmacology. 2021;419:115518.
[13] LI H S, XU Y. Inhibition of EZH2 via the STAT3/HOTAIR signalling axis contributes to cell cycle arrest and apoptosis induced by polyphyllin I in human non-small cell lung cancer cells. Steroids. 2020;164:108729.
[14] FENG F F, CHENG P, SUN C, et al. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Chinese journal of natural medicines. 2019;17(10):768-77.
[15] YANG Q, CHEN W, XU Y, et al. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicology and applied pharmacology. 2018;356:1-7.
[16] LIU Y, ZHANG W, ZHOU H, et al. Steroidal saponins PPI/CCRIS/PSV induce cell death in pancreatic cancer cell through GSDME-dependent pyroptosis. Biochemical and biophysical research communications. 2023;673:51-8.
[17] LUO Q, YANG D, QI Q, et al. Role of the Death Receptor and Endoplasmic Reticulum Stress Signaling Pathways in Polyphyllin I-Regulated Apoptosis of Human Hepatocellular Carcinoma HepG2 Cells. BioMed research international. 2018;2018:5241941.
[18] KURIAKOSE T, MAN S M, MALIREDDI R K, et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Science immunology. 2016;1(2).
[19] KESAVARDHANA S, KURIAKOSE T, GUY C S, et al. ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death. The Journal of experimental medicine. 2017;214(8):2217-29.
[20] MALIREDDI R K S, GURUNG P, MAVULURI J, et al. TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation. The Journal of experimental medicine. 2018;215(4):1023-34.
[21] MALIREDDI R K S, KESAVARDHANA S, KANNEGANTI T D. ZBP1 and TAK1: Master Regulators of NLRP3 Inflam-masome/Pyroptosis, Apoptosis, and Necroptosis (PAN-optosis). Frontiers in cellular and infection microbiology. 2019;9:406.
[22] MALIREDDI R K S, GURUNG P, KESAVARDHANA S, et al. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease. The Journal of experimental medicine. 2020;217(3).
[23] CHRISTGEN S, ZHENG M, KESAVARDHANA S, et al. Identification of the PANoptosome: A Molecular Platform Triggering Pyroptosis, Apoptosis, and Necroptosis (PANoptosis). Frontiers in cellular and infection microbiology. 2020;10:237.
[24] MALIREDDI R K S, KARKI R, SUNDARAM B, et al. Inflammatory Cell Death, PANoptosis, Mediated by Cytokines in Di-verse Cancer Lineages Inhibits Tumor Growth. ImmunoHorizons. 2021;5(7):568-80.
[25] KARKI R, SUNDARAM B, SHARMA B R, et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell reports. 2021;37(3):109858.
[26] KARKI R, SHARMA B R, LEE E, et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI insight. 2020;5(12).
[27] WEI S, CHEN Z, LING X, et al. Comprehensive analysis illustrating the role of PANoptosis-related genes in lung cancer based on bioinformatic algorithms and experiments. Frontiers in pharmacology. 2023;14:1115221.
[28] LI Y, QI D, ZHU B, et al. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival. International journal of molecular sciences. 2021;22(3).
[29] GIANNINI H M, GINESTRA J C, CHIVERS C, et al. A Machine Learning Algorithm to Predict Severe Sepsis and Septic Shock: Development, Implementation, and Impact on Clinical Practice. Critical care medicine. 2019;47(11):1485-92.
[30] SADOZAI H, ACHARJEE A, EPPENBERGER-CASTORI S, et al. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Frontiers in immunology. 2021;12:643529.
[31] WANG Y, HUANG Z, XIAO Y, et al. The shared biomarkers and pathways of systemic lupus erythematosus and metabolic syndrome analyzed by bioinformatics combining machine learning algorithm and single-cell sequencing analysis. Frontiers in immunology. 2022;13:1015882.
[32] CHEN T, GUESTRIN C. Xgboost: A scalable tree boosting system; proceedings of the Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining, F, 2016 [C].
[33] SUN D, WANG J, HAN Y, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic acids research. 2021;49(D1):D1420-d30.
[34] KIM N, KIM H K, LEE K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nature communications. 2020;11(1):2285.
[35] MILLER M, HANNA N. Advances in systemic therapy for non-small cell lung cancer. BMJ (Clinical research ed). 2021;375:n2363.
[36] TIAN Y, GONG G Y, MA L L, et al. Anti-cancer effects of Polyphyllin I: An update in 5 years. Chemico-biological interactions. 2020;316:108936.
[37] WELCH C, SANTRA M K, EL-ASSAAD W, et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer research. 2009;69(17):6782-9.
[38] XIONG T, LV X S, WU G J, et al. Single-Cell Sequencing Analysis and Multiple Machine Learning Methods Identified G0S2 and HPSE as Novel Biomarkers for Abdominal Aortic Aneurysm. Frontiers in immunology. 2022;13:907309.
[39] KUSAKABE M, KUTOMI T, WATANABE K, et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. International journal of cancer. 2010;126(8):1895-902.
[40] ZAGANI R, EL-ASSAAD W, GAMACHE I, et al. Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells. Oncotarget. 2015;6(29):28282-95.
[41] HATAE T, WADA M, YOKOYAMA C, et al. Prostacyclin-dependent apoptosis mediated by PPAR delta. The Journal of biological chemistry. 2001;276(49):46260-7.
[42] PAN X Y, YANG Y, MENG H W, et al. DNA Methylation of PTGIS Enhances Hepatic Stellate Cells Activation and Liver Fibrogenesis. Frontiers in pharmacology. 2018;9:553.
[43] LEI K, LIANG R, TAN B, et al. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma. Oxidative medicine and cellular longevity. 2023;2023:6811625.
[44] DAI D, CHEN B, FENG Y, et al. Prognostic value of prostaglandin I2 synthase and its correlation with tumor-infiltrating immune cells in lung cancer, ovarian cancer, and gastric cancer. Aging. 2020;12(10):9658-85.
[45] LIANG X, WANG J, LIU Y, et al. Polymorphisms of COX/PEG2 pathway-related genes are associated with the risk of lung cancer: A case-control study in China. International immunopharmacology. 2022;108:108763.
[46] MILOVIC-HOLM K, KRIEGHOFF E, JENSEN K, et al. FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. The EMBO journal. 2007;26(2):391-401.
[47] MELENOTTE C, MEZOUAR S, BEN AMARA A, et al. A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever. PloS one. 2019;14(6):e0217542.
[48] DUAN Y, DU Y, MU Y, et al. Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma. Aging. 2023;15(12):5569-91.
[49] BERSCHEMINSKI J, BRUN J, SPEISEDER T, et al. Sp100A is a tumor suppressor that activates p53-dependent transcription and counteracts E1A/E1B-55K-mediated transformation. Oncogene. 2016;35(24):3178-89.
[50] HELD-FEINDT J, HATTERMANN K, KNERLICH-LUKOSCHUS F, et al. SP100 reduces malignancy of human glioma cells. International journal of oncology. 2011;38(4):1023-30.
[51] DONNER I, KATAINEN R, SIPILä L J, et al. Germline mutations in young non-smoking women with lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands). 2018;122:76-82.
[52] KARKI R, SHARMA B R, TULADHAR S, et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021;184(1):149-68.e17.
[53] HUANG J X, WU Y C, CHENG Y Y, et al. IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells. OncoTargets and therapy. 2019;12:11475-86.
[54] JIN J, YU G. Hypoxic lung cancer cell-derived exosomal miR-21 mediates macrophage M2 polarization and promotes cancer cell proliferation through targeting IRF1. World journal of surgical oncology. 2022;20(1):241.
[55] ZHANG L, CHENG T, YANG H, et al. Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells. Medical oncology (Northwood, London, England). 2022;39(4):38.
[56] WU M, TU J, HUANG J, et al. Exosomal IRF1-loaded rat adipose-derived stem cell sheet contributes to wound healing in the diabetic foot ulcers. Molecular medicine (Cambridge, Mass). 2023;29(1):60.
[57] ORZALLI M H, SMITH A, JURADO K A, et al. An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication. Molecular cell. 2018;71(5):825-40.e6.
[58] WANG J, IKEDA R, CHE X F, et al. VEGF expression is augmented by hypoxia‑induced PGIS in human fibroblasts. International journal of oncology. 2013;43(3):746-54.
[59] SOMMERFELD L, KNUTH I, FINKERNAGEL F, et al. Prostacyclin Released by Cancer-Associated Fibroblasts Promotes Immunosuppressive and Pro-Metastatic Macrophage Polarization in the Ovarian Cancer Microenvironment. Cancers. 2022;14(24).
[60] YIM C Y, SEKULA D J, HEVER-JARDINE M P, et al. G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer research. 2016;76(5):1204-13.
[61] CHOI H, LEE H, KIM T H, et al. G0/G1 switch gene 2 has a critical role in adipocyte differentiation. Cell death and differentiation. 2014;21(7):1071-80.